Please login to the form below

Not currently logged in

Lilly bags EU approval for cancer treatment Lartruvo

Licensed for use with doxorubicin for soft tissue sarcoma patients
Eli Lilly

The European Commission has granted Lilly's Lartruvo (orlaratumab) marketing authorisation for the first-line treatment of patients with advanced soft tissue sarcoma (STS).

The monoclonal antibody is the first of its kind to receive a licence for STS, and ended a four-decade drought for new frontline therapies in this area when it won FDA accelerated approval in October.

Awarded a conditional licence by European regulators, Lartruvo will be administered in combination with chemotherapy drug doxorubicin in previously untreated adults with advanced STS not eligible for curative surgery or radiotherapy.

The EC's decision was based on phase II data from the JGDG trial, which showed the combination almost doubled survival, extending it to 26.5 months compared to 14.7 for doxorubicin alone.

Having awarded an accelerated approval, the EMA has requested additional data from the ongoing ANNOUNCE phase III study which is due to generate results in 2019. Until then, Lartruvo will be subject to an annual safety review by the CHMP.

Dr Sue Mahony, president of Lilly Oncology, said: “With this decision, olaratumab is now authorised for use in the EU, offering a new treatment option for soft tissue sarcoma patients in Europe.

“This news further reinforces Lilly's ongoing commitment toward these types of rare diseases and the patients that are affected around the globe.”

Article by
Rebecca Clifford

11th November 2016

From: Regulatory



Featured jobs

Subscribe to our email news alerts


Add my company

At Pegasus, we specialise in helping deliver healthy messages through integrated communication programmes. In fact, inspiring healthy decisions is all...

Latest intelligence

figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...
The rise of real-world evidence
Demonstrating efficacy and value requires more than clinical trial data...
Digital health
The untapped potential to transform healthcare...